Is Bruker Corp. overvalued or undervalued?

As of 30 June 2025, Bruker Corp. has moved from an expensive to a very expensive valuation grade. The company is overvalued, as indicated by its P/E ratio of 49, which significantly exceeds the peer average of 35.20 for similar companies, such as Hologic, Inc. with a P/E of 21.83 and The Cooper Cos., Inc. at 34.28. Additionally, Bruker Corp.'s EV to EBITDA ratio stands at 16.45, which is higher than the industry average, further supporting the overvaluation assessment.
The company's Price to Book Value is 3.68, suggesting that investors are paying a premium for its equity compared to its book value. Despite a high dividend yield of 32.93%, the overall financial metrics indicate that Bruker Corp. is not positioned favorably in comparison to its peers. Furthermore, the stock has underperformed against the S&P 500, with a year-to-date return of -43.24% compared to the index's 12.22%, reinforcing the notion that the stock is overvalued.